211 related articles for article (PubMed ID: 32471447)
1. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation.
Mishra G; Dev A; Paul E; Cheung W; Koukounaras J; Jhamb A; Marginson B; Lim BG; Simkin P; Borsaru A; Burnes J; Goodwin M; Ramachandra V; Spanger M; Lubel J; Gow P; Sood S; Thompson A; Ryan M; Nicoll A; Bell S; Majeed A; Kemp W; Roberts SK;
BMC Cancer; 2020 May; 20(1):483. PubMed ID: 32471447
[TBL] [Abstract][Full Text] [Related]
2. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
5. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
[TBL] [Abstract][Full Text] [Related]
6. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
8. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
9. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
Dettmer A; Kirchhoff TD; Gebel M; Zender L; Malek NP; Panning B; Chavan A; Rosenthal H; Kubicka S; Krusche S; Merkesdal S; Galanski M; Manns MP; Bleck JS
World J Gastroenterol; 2006 Jun; 12(23):3707-15. PubMed ID: 16773687
[TBL] [Abstract][Full Text] [Related]
10. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
11. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
12. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.
Jiang JH; Guo Z; Lu HF; Wang XB; Yang HJ; Yang FQ; Bao SY; Zhong JH; Li LQ; Yang RR; Xiang BD
World J Gastroenterol; 2015 Apr; 21(15):4627-34. PubMed ID: 25914472
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
15. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.
Eltawil KM; Berry R; Abdolell M; Molinari M
HPB (Oxford); 2012 Mar; 14(3):162-70. PubMed ID: 22321034
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study.
Eltawil KM; Berry R; Abdolell M; Molinari M
HPB (Oxford); 2012 May; 14(5):341-50. PubMed ID: 22487072
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of chemoembolization for recurrent HCC after curative ablation therapy.
Okabe N; Morimoto M; Kondo M; Moriya S; Numata K; Maeda S; Tanaka K
Hepatogastroenterology; 2013 May; 60(123):395-99. PubMed ID: 23108088
[TBL] [Abstract][Full Text] [Related]
18. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
[TBL] [Abstract][Full Text] [Related]
19. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.
Song BC; Suh DJ; Yang SH; Lee HC; Chung YH; Sung KB; Lee YS
J Clin Gastroenterol; 2002; 35(5):398-402. PubMed ID: 12394228
[TBL] [Abstract][Full Text] [Related]
20. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.
Mähringer-Kunz A; Weinmann A; Schmidtmann I; Koch S; Schotten S; Pinto Dos Santos D; Pitton MB; Dueber C; Galle PR; Kloeckner R
BMC Cancer; 2018 Apr; 18(1):489. PubMed ID: 29703174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
